Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  AIDS Research and Human Retroviruses

• Publication date

  2016-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/AID.2015.0130PMID 26150024PMCID PMC4761795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Treatment with Suppressive Combination Antiretroviral Drug Therapy and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid; (SAHA) on SIV-Infected Chinese Rhesus Macaques

  2014cited by this paper
• Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys

  2014cited by this paper
• Effect of Suberoylanilide Hydroxamic Acid (SAHA) Administration on the Residual Virus Pool in a Model of Combination Antiretroviral Therapy-Mediated Suppression in SIVmac239-Infected Indian Rhesus Macaques

  2014cited by this paper
• Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events

  2014cited by this paper
• Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies

  2013cited by this paper
• A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model

  2012cited by this paper
• Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension

  2011cited by this paper
• Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy

  2011cited by this paper
• Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

  2011cited by this paper
• The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

  2011cited by this paper
• Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy

  2010cited by this paper
• Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.

  2009cited by this paper
• Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1

  2009cited by this paper
• HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein.

  2008cited by this paper
• Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects

  2008cited by this paper
• Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials

  2008cited by this paper
• Rhesus Macaque Polyclonal and Monoclonal Antibodies Inhibit Simian Immunodeficiency Virus in the Presence of Human or Autologous Rhesus Effector Cells

  2006cited by this paper
• Tenofovir Disoproxil Fumarate

  2004cited by this paper
• Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

  2001cited by this paper
• Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults

  1998cited by this paper

• Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.

  2026cites this paper
• Gastrointestinal Mucosal Disruptions During ART-Treated SIV/Plasmodium fragile Co-Infection

  2026influential citation
• The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection

  2025cites this paper
• Origin and Correlates of Viral Rebound in SIV-Infected Rhesus Macaques Following ART Discontinuation

  2025cites this paper
• Identification of initial sites of SIV rebound after treatment cessation

  2025influential citation
• Inflammatory neutrophil responses and T cell activation in ART-treated SIVmac239-infected rhesus macaques

  2025cites this paper
• SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells

  2025cites this paper
• Plasma lipidomic alterations during pathogenic SIV infection with and without antiretroviral therapy

  2025cites this paper
• Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy.

  2025cites this paper
• An Immunocytochemistry Method to Investigate the Translationally Active HIV Reservoir

  2025cites this paper
• Contribution of intact viral genomes persisting in blood and tissues during ART to plasma viral rebound in SHIV-infected rhesus macaques

  2025cites this paper
• Dynamics of natural and pharmacologic control of an SIV variant with an envelope trafficking defect

  2025influential citation
• Whole-body distribution of tenofovir, emtricitabine and dolutegravir in non-human primates.

  2024cites this paper
• A dual-purpose humanized mouse model for testing antiviral strategies against both SIV and HIV

  2024cites this paper
• Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence

  2024cites this paper
• The Association between IL-1β and IL-18 Levels, Gut Barrier Disruption, and Monocyte Activation during Chronic Simian Immunodeficiency Virus Infection and Long-Term Suppressive Antiretroviral Therapy

  2024cites this paper
• Elevated Inflammation Associated with Markers of Neutrophil Function and Gastrointestinal Disruption in Pilot Study of Plasmodium fragile Co-Infection of ART-Treated SIVmac239+ Rhesus Macaques

  2024influential citation
• High IL-1β and IL-18 Levels Associate with Gut Barrier Disruption and Monocyte Activation During Chronic SIV Infection with Long-Term Suppressive Antiretroviral Therapy

  2024influential citation
• No evidence for ongoing replication on ART in SIV-infected macaques

  2024cites this paper
• Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy

  2024cites this paper
• Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir

  2024cites this paper
• Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies

  2024cites this paper
• Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV

  2023cites this paper
• 2-Hydroxypropyl-β-Cyclodextrin Treatment Induces Modest Immune Activation in Healthy Rhesus Macaques

  2023cites this paper
• Osteopontin is an integral mediator of cardiac interstitial fibrosis in models of HIV infection.

  2023cites this paper
• Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants.

  2023cites this paper
• Deep analysis of CD4 T cells in the rhesus CNS during SIV infection

  2023cites this paper
• Last in first out: SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells

  2023cites this paper
• Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir

  2023cites this paper
• CD4 T cell Responses in the CNS during SIV infection

  2023cites this paper
• Butyrate administration is not sufficient to improve immune reconstitution in antiretroviral-treated SIV-infected macaques

  2022cites this paper
• Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus–infected rhesus macaques on antiretroviral therapy

  2022cites this paper
• Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants

  2022cites this paper
• Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy

  2022cites this paper
• So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research

  2022cites this paper
• Expansion of Immature Neutrophils During SIV Infection Is Associated With Their Capacity to Modulate T-Cell Function

  2022cites this paper
• Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1

  2022cites this paper
• Frequent first-trimester pregnancy loss in rhesus macaques infected with African-lineage Zika virus

  2022cites this paper
• Pharmacological Validation of Long-Term Treatment with Antiretroviral Drugs in a Model of SIV-Infected Non-Human Primates

  2022cites this paper
• Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques

  2022cites this paper
• Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1

  2022cites this paper
• Multiple modes of antigen exposure induce clonotypically diverse epitope-specific CD8+ T cells across multiple tissues in nonhuman primates

  2022cites this paper
• HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure.

  2022cites this paper
• IL-21 and IFNα therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques

  2021cites this paper
• Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

  2021cites this paper
• Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

  2021cites this paper
• Dysregulation of IL-17/IL-22 Effector Functions in Blood and Gut Mucosal Gamma Delta T Cells Correlates With Increase in Circulating Leaky Gut and Inflammatory Markers During cART-Treated Chronic SIV Infection in Macaques

  2021cites this paper
• CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

  2021cites this paper
• Lack of Specific Regulatory T Cell Depletion and Cytoreduction Associated with Extensive Toxicity After Administration of Low and High Doses of Cyclophosphamide

  2021cites this paper
• Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir

  2021cites this paper
• Gut Microbiome Changes Associated with Epithelial Barrier Damage and Systemic Inflammation during Antiretroviral Therapy of Chronic SIV Infection

  2021cites this paper
• A Gut Reaction to SIV and SHIV Infection: Lower Dysregulation of Mucosal T Cells during Acute Infection Is Associated with Greater Viral Suppression during cART

  2021cites this paper
• New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models

  2021cites this paper
• Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques

  2021cites this paper
• Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model

  2021cites this paper
• Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity

  2020cites this paper
• Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection

  2020cites this paper
• Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation

  2020cites this paper
• N-Acetylcysteine Reverses Antiretroviral-Mediated Microglial Activation by Attenuating Autophagy-Lysosomal Dysfunction

  2020cites this paper
• SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques

  2020cites this paper
• Innovative HBV Animal Models Based on the Entry Receptor NTCP

  2020cites this paper
• Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus

  2020influential citation
• Robust Expansion of HIV CAR T Cells Following Antigen Boosting in ART-Suppressed Nonhuman Primates.

  2020cites this paper
• Anti-retroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV co-infection model.

  2020cites this paper
• Atrophy and death of non-peptidergic and peptidergic nociceptive neurons in SIV infection.

  2020cites this paper
• CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption

  2020cites this paper
• The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes.

  2020cites this paper
• Analytical treatment interruption after short-term anti-retroviral therapy in a postnatally SHIV infected infant rhesus macaque model

  2019cites this paper
• Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies

  2019cites this paper
• Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model

  2019cites this paper
• A Tat/Rev Induced Limiting Dilution Assay to Measure Viral Reservoirs in Non-Human Primate Models of HIV Infection

  2019cites this paper
• The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

  2019cites this paper
• Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials

  2019cites this paper
• Mass Cytometry Reveals the Immaturity of Circulating Neutrophils during SIV Infection

  2019cites this paper
• TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia.

  2019cites this paper
• FOXO1 transcription factor plays a key role in T cell—HIV-1 interaction

  2019cites this paper
• STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques

  2019cites this paper
• Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound

  2018cites this paper
• In Vitro and In Vivo Models of HIV Latency.

  2018cites this paper
• Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.

  2018cites this paper
• Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART)

  2018cites this paper
• Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27CA

  2018cites this paper
• Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques

  2018cites this paper
• Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes

  2018cites this paper
• Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation

  2018cites this paper
• Tackling HIV and AIDS: contributions by non-human primate models

  2017cites this paper
• Tackling HIV and AIDS: contributions by non-human primate models

  2017cites this paper
• Wake me up before you go: a strategy to reduce the latent HIV reservoir.

  2017cites this paper
• Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee

  2017cites this paper
• In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.

  2017cites this paper
• Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy

  2017cites this paper
• Quantifying integrated SIV-DNA by repetitive-sampling Alu-gag PCR

  2016cites this paper
• Animal models to achieve an HIV cure

  2016cites this paper
• Latency reversal and viral clearance to cure HIV-1

  2016cites this paper
• Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis

  2016cites this paper
• Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers

  2016cites this paper
• Animal Models for HIV Cure Research

  2016cites this paper
• Non-human primates in HIV research: Achievements, limits and alternatives.

  2016cites this paper
• SIV infected chimpanzees: Consequences of long-term infection and potential intervention strategies

  2016cites this paper
• Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy

  2015cites this paper